181 related articles for article (PubMed ID: 15455449)
1. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.
Berman B; Seeberger L; Kumar R
Mov Disord; 2005 Feb; 20(2):233-7. PubMed ID: 15455449
[TBL] [Abstract][Full Text] [Related]
2. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation.
Racette BA; McGee-Minnich L; Perlmutter JS
Clin Neuropharmacol; 1999; 22(6):337-9. PubMed ID: 10626093
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
6. Outcome of selective ramisectomy for botulinum toxin resistant torticollis.
Ford B; Louis ED; Greene P; Fahn S
J Neurol Neurosurg Psychiatry; 1998 Oct; 65(4):472-8. PubMed ID: 9771768
[TBL] [Abstract][Full Text] [Related]
7. Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.
Skogseid IM; Røislien J; Claussen B; Kerty E
Mov Disord; 2005 Dec; 20(12):1604-9. PubMed ID: 16114026
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cervical dystonia with botulinum toxin.
Jankovic J
Mov Disord; 2004 Mar; 19 Suppl 8():S109-15. PubMed ID: 15027062
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
Factor SA; Molho ES; Evans S; Feustel PJ
Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
[TBL] [Abstract][Full Text] [Related]
12. Reply: Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial.
Mueller J
Mov Disord; 2009 May; 24(7):1098-9; author reply 1100. PubMed ID: 18942082
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
[TBL] [Abstract][Full Text] [Related]
14. [Dose-response relationship in the treatment of cervical dystonia with botulinum toxin type A (AGN 191622)--a phase II study].
Mezaki T; Kaji R; Kimura J; Mannen T
No To Shinkei; 1995 Sep; 47(9):857-62. PubMed ID: 7546934
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
Figgitt DP; Noble S
Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.
Lew MF; Adornato BT; Duane DD; Dykstra DD; Factor SA; Massey JM; Brin MF; Jankovic J; Rodnitzky RL; Singer C; Swenson MR; Tarsy D; Murray JJ; Koller M; Wallace JD
Neurology; 1997 Sep; 49(3):701-7. PubMed ID: 9305326
[TBL] [Abstract][Full Text] [Related]
18. Effect of botulinum toxin injection for achalasia in Thai patients.
Leelakusolvong S; Sinpeng T; Pongprasobchai S; Tanwandee T; Kachintorn U; Manatsathit S
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S67-72. PubMed ID: 17718248
[TBL] [Abstract][Full Text] [Related]
19. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.
Jankovic J; Hunter C; Dolimbek BZ; Dolimbek GS; Adler CH; Brashear A; Comella CL; Gordon M; Riley DE; Sethi K; Singer C; Stacy M; Tarsy D; Atassi MZ
Neurology; 2006 Dec; 67(12):2233-5. PubMed ID: 17190952
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin treatment of axial and cervical dystonia.
Benecke R; Dressler D
Disabil Rehabil; 2007 Dec; 29(23):1769-77. PubMed ID: 18033602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
